Atlas Trials

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Clinical trial NCT02876302 · COMPLETED

Trial details

NCT number
NCT02876302
Sponsor
Dana-Farber Cancer Institute
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Inflammatory Breast Cancer (IBC)
Start date
2018-01-24
Primary completion
2022-12-31
Enrollment
23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.